Clinical Trial Search

Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097

Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence

Primary: Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach — 234.5 Ratio

Primary: Successful Infection of Vector Mosquitoes Following Both Direct and Indirect Feeding on the Blood of Infected Participants

Primary: Participants With Local Adverse Events (AEs) - Year One — 3; 1; 0; 0 Participants

Primary: P. Vivax Blood Collection — 2 Participants

Primary: Frequency of Adverse Events in the CHMI-trans Model — 95; 95; 107; 52 Adverse events

Primary: Number of Participants With Positive Sensitive Blood Smear (sBS) — 0; 0 Participants

Primary: Number of Participants With Local and Systemic Adverse Events in Years 1 and 2 — 15; 14; 15; 15 Participants

Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation of Study Treatment — 13; 6; 5; 3…

Primary: Time to First PCR-detectable Malaria Infection During the Active Detection of Infection (ADI) Phase in Groups 1 and 4 — 1.01; 1.49 Events per person year at risk — p=0.009

Primary: The Activity of Single Oral Doses of MMV533 (Name of Investigational Medicinal Product) on Clearance of Plasmodium — 42.17; 158.03; 187.57 PRR48=parasite reduction ratio…

Primary: Number of Participants With Local Adverse Events (AEs) — 0; 1; 1; 1 Participants

Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events

Primary: Time From First Vaccination to the Detection of the First New Malaria Infection Through to the Month 20 Study Visit — 43.1; 43.9; 39; 39 Weeks

Primary: Number of Subjects With Plasmodium Falciparum (P. Falciparum) Parasitaemia (PFP), by Study Center — 235; 153; 167; 141 Participants

Primary: Number of Participants With P.Falciparum Blood Stage Infection — 0; 0; 0; 0 Participants

Primary: Number of Participants With Local and Systemic Adverse Events in Year One — 39; 27; 19; 11 Participants

Primary: Malaria Diagnosis Using RealAmp and Microscopy. — 42; 153; 0; 1 Participants

Primary: Plasmodium Falciparum Peripheral Parasitemia — 8; 7 Participants

Primary: Number of Participants With Local Adverse Events (AEs) — 7; 1; 0; 0 Participants

Primary: Efficacy of the ChAd63 and MVA PvDBP Vaccines, Administered in a Heterologous Prime-boost Regimen, Assessed by a Reduced Parasite Multiplication Rate in Vaccinated…

Primary: Incidence of Placental Malaria Infection Based on Histology — 11.58; 15.42; 15.42 percentage of pregnancies — p=0.2441

Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants

Primary: Participants With Local Adverse Events (AEs) — 1; 0; 0; 2 Participants

Primary: Number of Participants With Adverse Events Within 7 Days After Each Vaccine Administration — 51; 43; 43 Participants

Primary: Number of Participants With Local and Systemic Adverse Events in Year 1 — 2; 6; 4; 6 Participants

Primary: Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms — 93.4; 93.7 g/L

Primary: Emax — 0.201 Maximum clearance rate (1/hour)

Primary: To Characterize the Infectivity of a New Lot of Plasmodium Falciparum Strain 3D7 Developing Parasitemia Within the Standard WRAIR CHMI Model. — 0; 1; 5; 5 Participants